Navigation Links
Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
Date:6/20/2016

IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody discovery, and immuno-oncology research, announced a collaboration with Notable Labs to further the development of a predictive personalized medicine platform.

Notable Labs helps oncologists identify effective therapies that they can prescribe today by testing them on a patient’s own cells. This approach promises tailored treatment options fast enough for doctors to put to use. By testing a broad set of drugs and drug combinations, Notable Labs is able to functionally profile cancer cells, which leads to a better understanding of the biological mechanisms of the patient’s cancer. Providing this information to physicians can improve treatment outcomes while reducing side effects.

Notable Labs will utilize IntelliCyt’s iQue® Screener PLUS platform in a fully automated, high-throughput laboratory to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Prioritized treatment options will be highlighted in reports to clinicians using Notable Lab’s screening process with IntelliCyt’s immune-profiling technology.

The IntelliCyt iQue Screener platform, an integrated instrument, software and reagent system, offers a proprietary high-throughput sampling capability that enables the rapid assessment of cells and beads in suspension in 96-, 384-, and 1536-well plates. In addition to the fastest plate processing speed in the industry today for this type of analysis, miniaturization of the assay is possible to save reagent cost and conserve precious samples. Additionally, high content, multiplex readouts are generated on each individual cell or bead via the flow cytometry-based detection system. Data analysis and visualization using ForeCyt® software, provides unique insights into the complex biology of disease.

“IntelliCyt is expanding into the personalized medicine field by leveraging our high throughput, immune-profiling capabilities,” said Janette Phi, Chief Business Officer of IntelliCyt. “We are excited to collaborate with Notable Labs in this transformational path of enabling potentially life-saving therapies.”

“The iQue Screener PLUS offers deeper insights into which treatments target cancer cells while sparing a patient’s healthy cells”, said Matt De Silva, CEO of Notable Labs. “High-throughput flow cytometry provides us with new capabilities to observe real-time drug sensitivity for individual patients on a single cell level.”

About Notable Labs
Our mission is to change the way cancer is treated, which starts with putting patients first. Combining FDA-approved treatment options with laboratory automation and data science, we’ve built a service to help oncologists identify effective therapies that they can prescribe today. For more information, please visit http://www.notablelabs.com.

About IntelliCyt
IntelliCyt Corporation manufactures and sells instrumentation, software and reagents that facilitate the study of cells and their components to gain a better understanding of normal and disease processes. This information speeds the discovery and development of new drugs and provides new insight for the diagnosis of diseases. IntelliCyt’s products are used worldwide throughout the pharmaceutical and biotechnology industries and in nonprofit research labs. For more information, please visit http://www.intellicyt.com.

# # #

Read the full story at http://www.prweb.com/releases/2016/06/prweb13493909.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Fumio Hirakawa has been awarded with the notable Golden A' Design Award
2. Massachusetts General Hospital Enters Into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
3. Molecular Imaging of Colorado Joins Integrated Diagnostic Centers’ Denver Radiology Network
4. AstraZeneca Enters into an Agreement with IntelliCyt for the Development of High Throughput Biology Applications
5. Arrowhead Health Centers at the Forefront of Pain Management with Use of Regenerative Cell-based Therapies to Treat Chronic Pain
6. Genisphere Enters Collaborative Research Agreement with the University of Pennsylvania
7. Bionik Laboratories Enters into Merger Agreement to Acquire Interactive Motion Technologies, Inc. (IMT)
8. Trovagene Enters into Preferred Provider Agreement with Three Rivers Provider Network
9. Trovagene Enters into Preferred Provider Agreement with Fortified Provider Network
10. Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform
11. F-star Enters Into Collaborative Discovery & Development Agreement With AbbVie for Bispecific Antibodies in Immuno-oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2018)... ... 20, 2018 , ... Superior Controls, Inc. , a ... 150 employees on both the east and west coasts, today announced the company ... the high criteria for application expertise, operational excellence and a very strong 20-year ...
(Date:10/13/2017)... ... October 13, 2017 , ... Turesol Staffing Solutions announced today that ... a discussion on the subject of “Process capabilities as they apply to the pharmaceutical ... theme of this year’s meeting is “Driving innovation to advance patient therapies,” and the ...
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik ... Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... Foundation and administered by the New York Academy of Sciences to honor the ...
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):